India’s Clinical Trial Inflection Point: A Sponsor’s Guide

Webinar overview

India is drawing growing attention from early stage sponsors, yet many still hesitate over regulatory approvals, data quality, speed, and cost. In this panel, a US biotech executive puts those concerns directly to the people who run early stage trials in India.

Expect candid answers, a closer look at radiopharma, and a real case study. Register to hear what has changed in India and what sponsors should check before they commit.

What you will learn

1. 01

   What has changed in India’s approval process, and how the FDA views Indian regulatory approvals and data

2. 02

   How to judge the quality of a site’s data, including what belongs on a sponsor’s due diligence checklist

3. 03

   How India compares with other emerging markets on speed and cost per patient, and whether it supports Phase II and III trials as well as Phase I

4. 04

   Whether India is well suited to radiopharma trials, and where the key oncology centers are

5. 05

   How an early stage trial runs in practice, through a Karkinos case study

6. 06

   Plus a bonus: every participant can download our recently published white paper

Speakers

Who should attend

• Early stage biotech and pharma sponsors in the US and EMEA, especially in oncology and radiopharma
• Chief medical officers, clinical development leaders, clinical operations, and regulatory teams
• Research institutes in the US and Europe looking to collaborate with Indian partners
• Indian sites and institutes that want to work with international sponsors